Sign In
Buy BMRN
$54.66
+1.34 (+2.51%)
At Close: Jun 03, 2026
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical (BMRN) Stock?
09:47am, Wednesday, 08'th Mar 2023
Investors need to pay close attention to BioMarin Pharmaceutical (BMRN) stock based on the movements in the options market lately.
FDA now set to decide on BioMarin's hemophilia drug by June 30
07:42am, Tuesday, 07'th Mar 2023
BioMarin Pharmaceutical Inc. BMRN, -6.82% said Tuesday that the Food and Drug Administration pushed back the deadline to make a decision whether to approve the company's experimental gene therapy for
Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics
03:47am, Tuesday, 28'th Feb 2023
The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended December 2022, but it may be worthwhile to compare some of its key metrics to Wall Street esti
BioMarin Pharmaceutical Inc. (BMRN) Q4 2022 Earnings Call Transcript
09:19pm, Monday, 27'th Feb 2023
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q4 2022 Results Conference Call February 28, 2023 4:30 PM ET Company Participants Traci McCarty - Group VP, IR JJ Bienaimé - Chairman and CEO Jeff Ajer - E
BioMarin Pharmaceutical (BMRN) Q4 Earnings Lag Estimates
06:49pm, Monday, 27'th Feb 2023
BioMarin (BMRN) delivered earnings and revenue surprises of -7.69% and 0.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
BMRN Stock An Example Of Stock Market Character Change
04:13pm, Friday, 03'rd Feb 2023
With subsequent follow-through days mounting and stocks refusing to give up ground, this rally is showing it might be for real. The post BMRN Stock An Example Of Stock Market Character Change appeared
BioMarin: Priced For Perfection
07:28pm, Tuesday, 31'st Jan 2023
BioMarin has a core cadre of molecules with modestly growing revenues. Its VOXZOGO has clear blockbuster potential.
BioMarin: Opportunity To Score Home Run With Latest Regulatory Advancements
06:53pm, Monday, 30'th Jan 2023
BioMarin Pharmaceutical Inc. revenues for Q3 of 2022 came in at $505.3 million, which was a year-over-year growth of 24%. It has potential to receive U.S. marketing approval of ROCTAVIAN for the treat
Protagonist Therapeutics (PTGX) Moves 10.7% Higher: Will This Strength Last?
08:24am, Wednesday, 25'th Jan 2023 Zacks Investment Research
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further p
3 Drug Stocks With Promising Pipelines for 2023
10:03am, Monday, 23'rd Jan 2023
The world of pharmaceutical progress happens incrementally and exponentially. That is, therapies are iteratively improved while breakthrough treatments are also created and discovered.
Investing in Biotech ETFs
04:56pm, Friday, 20'th Jan 2023 The Motley Fool
Here are the five best biotech ETFs to invest in right now.
Should Schwab U.S. MidCap ETF (SCHM) Be on Your Investing Radar?
11:20am, Monday, 16'th Jan 2023 Zacks Investment Research
Style Box ETF report for SCHM
Cramer Is Holding This Biotech Stock
02:16pm, Thursday, 12'th Jan 2023 Benzinga
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended holding Biomarin Pharmaceutical Inc (NASDAQ: BMRN).
When asked about Black Stone Minerals LP (NYSE: BSM), he said, "I like this situat
BioMarin's Growth Prospects Soar with Potential Voxzogo and Roctavian Launches, Analyst Raises Price Target
07:49pm, Wednesday, 11'th Jan 2023 Benzinga
Wedbush has increased the price target on BioMarin Pharmaceutical Inc (NASDAQ: BMRN) from $74 to $84 while reiterating the Neutral rating.
BioMarin reported three-year Phase 3 GENEr8-1 results f
6 Analysts Have This to Say About Biomarin Pharmaceutical
06:00pm, Wednesday, 11'th Jan 2023 Benzinga
Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
4
1
0
0
